Body

Treatment she can plan on.

In the RAPID 1 RA trial, 59% of CIMZIA 200 mg Q2W + MTX-treated patients (n=393) vs. 14% of placebo + MTX-treated patients (n=199) achieved ACR20 at week 24.1

 
For moderate to severe RA patients

CIMZIA® (certolizumab pegol) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA).

NEXT: CIMZIA Design
RA